TRI-PHARMA, INC.

TRI-PHARMA, INC. specializes in the manufacturing of pharmaceutical preparations and the provision of hospital-based medical services, operating at the intersection of drug production and clinical care delivery. The company demonstrates technical expertise in GMP-compliant pharmaceutical manufacturing, including the formulation and production of injectable therapeutics such as SANDOSTATIN, as well as operational support for general medical and surgical hospital environments. Their capabilities include end-to-end pharmaceutical supply chain coordination, sterile product handling, and compliance with FDA and DEA regulatory frameworks for controlled substances. A key differentiator lies in their ability to bridge manufacturing precision with clinical delivery needs, ensuring timely, compliant access to critical medications within institutional healthcare settings. The contractor has delivered services to the Department of Veterans Affairs and the Department of Health and Human Services, indicating a focused presence in federal healthcare systems. For the VA, they provide specialized pharmaceutical products used in veteran care, while for HHS, they support hospital infrastructure and service delivery, suggesting alignment with public health initiatives and acute care network requirements. Their relationship with these agencies reflects a pattern of mission-critical supply and operational support rather than broad administrative contracting. Their primary industry focus is on NAICS 325412 (pharmaceutical preparation manufacturing) and 622110 (general medical and surgical hospitals), positioning them as a niche provider that integrates drug production with institutional healthcare operations. This dual focus enables them to serve as a vertical specialist in closed-loop pharmaceutical distribution within federally funded medical facilities. TRI-PHARMA, INC. is structured as a small business (2L entity) headquartered in Kennesaw, Georgia, with no federal certifications on record. Their geographic footprint is concentrated in the southeastern U.S., and they maintain a targeted presence in the federal healthcare market through direct contract performance rather than broad subcontracting networks.